Domains

Creating value across our world of Food & Beverages to Pharmaceuticals
Introducing the 3 business domains of the Kirin Group Creating value across our world of Food & Beverages to Pharmaceuticals Introducing the 3 business domains of the Kirin Group

Expanding the business domains based on fermentation and biotechnology

Since its founding in 1907, the Kirin Group has continued to grow for over 100 years.

Starting from the beer business, the company expanded into the Food & Beverages domain, and from the 1980s, fermentation and biotechnology have been used to expand into the Pharmaceuticals and Health Science domains. The Kirin Group is working to provide products and services that increase the quality of life for consumers in all of their life stages and at the same time solve the social issues.

Kirin Group brands spanning the globe

Since its founding, the Kirin Group has remained connected to consumers through products and services and is offering numerous brands in various regions and countries around the world.

In the Food & Beverages domain, the Kirin Group has expanded into overseas markets mainly in Asia and Oceania and is well-known and loved by many consumers.
Recently in the Health Science domain, highly functional products and services that utilize the group’s strengths have been developed.

Resolve key issues in business domains

Business domains and value provided
Social problems to be solved
Approach
Business vision for each business
Food & Beverages domain Form bonds between people and revitalize communities through our alcoholic beverages and soft drinks.
Contribute to well-being for consumers' daily life through Food and Beverages
A Responsible Alcohol Producer Responsible drinking / passing a culture of enjoying alcoholic beverages to the next generation
Established strong brand
equity and profit base
Health and well-being Expansion of sales of no- and low-sugar, low-calorie products
Continuously create ingredients with positive health effects and thereby create new value
Community Engagement We will create and increase opportunities that bring people together
The Environment Introduce renewable energy and promote energy conservation
Strive to maintain the 3Rs and resource circulation for containers and packaging
Health Science domain Maintaining health through Food and Beverages by preventing disease and suppressing its progression Health and well-being Continuously create ingredients with positive health effects and thereby create new value
Establish the unique business model
leveraging our strengths
The Environment Realize sustainable sourcing of biological resources and environmental conservation by fermentation production technology
Pharmaceuticals domain Develop the new drug by cutting-edge biotechnology. Restoration of health through personalized treatment and aftercare Health and well-being Deliver the new drug discovered in-house globally
Leaping Forward for
Global Specialty
Pharmaceutical Company
The Environment Introduce renewable energy and Water consumption reduction

While assuring growth in the Food & Beverages and Pharmaceuticals domains, establish the Health Science domain as a new pillar

Under the Long-Term Management Vision “Kirin Group Vision 2027 (KV2027)” established in 2019, the Kirin Group is aiming to become a global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.
As economic value, although the businesses have been affected by COVID-19, the Kirin Group is still aiming to achieve the original target set for 2027, normalized operating profit CAGR of 4-6% compared to 2018.
In addition to the existing pillars of Food & Beverages and Pharmaceuticals, the Health Science domain will be established as a new pillar. In these three domains, the Kirin Group will work to solve the issues facing society and realize sustainable growth.

Food & Beverages

Products and services that bring people together

This domain is the foundation of the Kirin Group, and efforts are being made to further enhance the profitability. The market for high margin beer business is gradually declining in Japan and Australia, so the product and service mix is being restructured to increase the share of higher value added products and services. In particular, the initiatives for craft beer, which has high growth potential, are being strengthened in Japan and overseas.

In the soft drinks business, although its core business successfully improved the profitability during the 2016-2018 Medium-Term Business Plan, the market environment is becoming more challenging. From a long-term perspective, aimed at positioning the non-alcoholic beverages business to play a larger role in the Health Science domain, the component ratio of brands with added health and well-being value is being increased.

Our core targets of SDGs

  • GOAL 3: Good Health and Well-being
  • GOAL 17: Partnerships to achieve the Goal

Key non-financial performance indicators(2021)

Increase in sales volume of non-alcohol and low-alcohol beverages

115 % (compared with 2018)

Key financial performance indicators(2027)

Food & Beverages domain:

Kirin Brewery
Normalized operating profit margin

25 % or higher

  • Sales revenue after liquor tax

View more

Health Science

Products and services that contribute to increasing quality of life

Through many years of research into natural ingredients, cells and microorganisms, the Kirin Group has succeeded in discovering numerous materials that contribute to health and well-being, such as Lactococcus lactis strain Plasma (LC-Plasma). The Health Science domain will utilize these unique materials to address the social issues of health and well-being.

While creating synergies between Kyowa Kirin and FANCL, the Kirin Group will establish a unique business model and aim to achieve a higher profit growth rate than the Food & Beverages and Pharmaceuticals domains.

Our core targets of SDGs

  • GOAL 3: Good Health and Well-being
  • GOAL 17: Partnerships to achieve the Goal

Key non-financial performance indicators(2021)

Development and expansion of sales of products containing ingredients proven to have health functions.

115 % (compared with 2018)

Key financial performance indicators(2027)

Health Science domain:

Revenue

2,000 billion yen

Normalized operating profit margin

15 % or higher

View more

Pharmaceuticals

Continuing to discover innovative new drugs

Kyowa Kirin, from the Pharmaceuticals domain, was created through a merger between Kyowa Hakko Kogyo and Kirin Pharma Co., Ltd., which originated from Kirin Brewery’s pharmaceuticals division. Kyowa Kirin is a research and development style company that utilizes state of the art biotechnology centered on antibody technology. As one of Japan’s major life science companies, Kyowa Kirin will always pursue new possibilities and strive to contribute to the health and well-being of people around the world by creating new value.
In the 2021-2025 Medium-Term Business Plan, “Provide pharmaceuticals for unmet medical needs”, “Address patient-centric healthcare needs” and “Retain the trust of society” have been set forth as the three strategies, and the Pharmaceuticals domain is expected to drive the growth of the Kirin Group over the medium-term.

Our core targets of SDGs

  • GOAL 3: Good Health and Well-being
  • GOAL 17: Partnerships to achieve the Goal

Key non-financial performance indicators(2021)

Number of in house drug discoveries maeketed in multiple regions:

Number of countries with markets for these new drugs

Three or more

products marketed in multiple regions

Number of countries with markets for these new drugs:

Over 50 countries in total

Key financial performance indicators(2025)

Pharmaceuticals domain:

Revenue growth

CAGR 10 % or higher

Core Operating profit margin

25 % or higher

View more

Value Creation Story

The Kirin appears as a prelude to joyous times to come

Kirin Group is working to solve a wide range of social issues around the world.
The following introduces the "value creation" story from the perspective of several fields.

PICKUP